BACKGROUND/AIMS: Interferon (IFN) therapy leads to regression of hepatic fibrosis in chronic hepatitis C patients who achieve a sustained virologic response (SVR), while the beneficial effect is limited in those who fail to do so. The aim of the present study was to define factors associated with progression of fibrosis in patients who do not achieve a SVR. METHODS: Fibrosis staging scores were compared between paired liver biopsies before and after IFN in 97 chronic hepatitis C patients who failed therapy. The mean interval between biopsies was 5.9 years. Factors associated with progression of fibrosis were analyzed. RESULTS: Fibrosis progressed in 23%, remained unchanged in 47% and regressed in 29%. Steatosis and a high average alanine aminotransferase (ALT) between biopsies were independent factors for progression of fibrosis with risk ratios of 5.53 and 4.48, respectively. Incidence and yearly rate of progression of fibrosis was 64% and 0.22+/-0.29 fibrosis units per year in those with both risk factors compared to 8% and -0.04+/-0.17 fibrosis units per year in those negative for both factors. CONCLUSIONS: Hepatic steatosis and elevated ALT levels are risk factors for progression of fibrosis in chronic hepatitis C patients who fail to achieve a SVR to IFN therapy and therefore may be therapeutic targets to halt the potentially progressive disease.
BACKGROUND/AIMS: Interferon (IFN) therapy leads to regression of hepatic fibrosis in chronic hepatitis Cpatients who achieve a sustained virologic response (SVR), while the beneficial effect is limited in those who fail to do so. The aim of the present study was to define factors associated with progression of fibrosis in patients who do not achieve a SVR. METHODS:Fibrosis staging scores were compared between paired liver biopsies before and after IFN in 97 chronic hepatitis Cpatients who failed therapy. The mean interval between biopsies was 5.9 years. Factors associated with progression of fibrosis were analyzed. RESULTS:Fibrosis progressed in 23%, remained unchanged in 47% and regressed in 29%. Steatosis and a high average alanine aminotransferase (ALT) between biopsies were independent factors for progression of fibrosis with risk ratios of 5.53 and 4.48, respectively. Incidence and yearly rate of progression of fibrosis was 64% and 0.22+/-0.29 fibrosis units per year in those with both risk factors compared to 8% and -0.04+/-0.17 fibrosis units per year in those negative for both factors. CONCLUSIONS:Hepatic steatosis and elevated ALT levels are risk factors for progression of fibrosis in chronic hepatitis Cpatients who fail to achieve a SVR to IFN therapy and therefore may be therapeutic targets to halt the potentially progressive disease.
Authors: Sekou R Rawlins; Ola El-Zammar; J Michael Zinkievich; Nancy Newman; Robert A Levine Journal: Dig Dis Sci Date: 2010-05-12 Impact factor: 3.199
Authors: Monica A Konerman; Yiwei Zhang; Ji Zhu; Peter D R Higgins; Anna S F Lok; Akbar K Waljee Journal: Hepatology Date: 2015-03-20 Impact factor: 17.425
Authors: Anna S Lok; James E Everhart; Raymond T Chung; Hae-Young Kim; Gregory T Everson; John C Hoefs; Joel K Greenson; Richard K Sterling; Karen L Lindsay; William M Lee; Adrian M Di Bisceglie; Herbert L Bonkovsky; Marc G Ghany; Chihiro Morishima Journal: Hepatology Date: 2009-06 Impact factor: 17.425